Details:
QBECO-SSI treatment, which is designed to restore normal innate immune function, immune homeostasis, and barrier function in the GI tract, provides a novel potentially transformative alternative to immunosuppressive therapies for patients living with IBD.
Lead Product(s): QBECO-SSI
Therapeutic Area: Gastroenterology Product Name: QBECO-SSI
Highest Development Status: Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Karolinska Institute
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 14, 2022
Details:
This new equity funding that will allow team and play an essential role in initiating three new Phase 2 randomized placebo-controlled clinical studies of Qbeco. Two of these important trials are in critical indications for which there are no effective treatments.
Lead Product(s): Qbeco
Therapeutic Area: Gastroenterology Product Name: Qbeco SSI
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $12.0 million Upfront Cash: Undisclosed
Deal Type: Financing March 21, 2022
Details:
The registration and commercialization of Tetra's various prescription products (REDUVO™ AdVersa®, QIXLEEF™ and CAUMZ™) across Avicanna's channels in Latin/South America. This opens the door for Tetra to initiate sales earlier than planned.
Lead Product(s): Tetrahydrocannabinol
Therapeutic Area: Gastroenterology Product Name: Reduvo AdVersa
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Tetra BioPharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership February 14, 2022
Details:
Tetra will use the Adversa® technology to develop a THC-based mucoadhesive film containing its PPP-002 (Dronabinol) drug candidate for the treatment of chemotherapy-induced nausea and vomiting.
Lead Product(s): Tetrahydrocannabinol
Therapeutic Area: Gastroenterology Product Name: PPP-002
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Tetra BioPharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 21, 2020
Details:
Devonian announced that the US Patent and Trademark Office has issued a Notice of Allowance for patent titled “Thylakoid Extract Composition and Formulation for the Treatment of Inflammatory Bowel Disease" covering the use of Thykamine™ for the treatment of Ulcerative Colitis.
Lead Product(s): Thylakoid extract
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 15, 2020